Abstract
Incidence and prevalence of Alzheimer Disease (AD) will rise in a accelerating fashion through the middle of the 21st century. Increased understanding of the pathological cascades in AD, and the knowledge that the initial brain changes begin years prior to clinical manifestations, have led to initiation of trials to prevent AD. With many of the designs being used or contemplated, prevention trials will involve repeated cognitive and functional assessments over years, require cooperation and collaboration of both the subject and a partner or proxy, and represent a substantial time and resource investment by the research team. Compliance with the study regimen and adherence to the protocol are thus major foci for study efficiency and success. In this section methods by which compliance and adherence can be optimized are discussed. Research on the effectiveness of these and other evolving methods will be of help in assuring success of such large scale studies in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
